Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hamer

Showing results (261-270 of 267) with videos related to

Pageof 27
Sort By:
You have reached the last page of results.This site can display upto 267 results.
Nature|July 17, 2019
Author Correction: Resonantly hybridized excitons in moiré superlattices in van der Waals heterostructuresEvgeny M Alexeev, David A Ruiz-Tijerina, Mark Danovich, et al.
The Lancet. Microbe|February 15, 2025
Safety and immunogenicity of an adjuvanted chikungunya virus virus-like particle (CHIKV VLP) vaccine in previous recipients of other alphavirus vaccines versus alphavirus vaccine-naive controls: an open-label, parallel-group, age-matched, sex-matched, phase 2 randomised controlled studyMelinda J Hamer, James M McCarty, Benjamin C Pierson, et al.
The Lancet. Infectious Diseases|August 17, 2024
Safety and immunogenicity of a next-generation live-attenuated yellow fever vaccine produced in a Vero cell line in the USA: a phase 1 randomised, observer-blind, active-controlled, dose-ranging clinical trialKayvon Modjarrad, Paul T Scott, Melanie McCauley, et al.
The Lancet. Infectious Diseases|June 30, 2023
Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trialMichael A Koren, Leyi Lin, Kenneth H Eckels, et al.
Lancet (London, England)|January 28, 2023
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trialMelinda J Hamer, Katherine V Houser, Amelia R Hofstetter, et al.
Nature Communications|August 7, 2023
Urbanisation generates multiple trait syndromes for terrestrial animal taxa worldwideAmy K Hahs, Bertrand Fournier, Myla F J Aronson, et al.
Nature|November 13, 2024
Biodiversity impacts of the 2019-2020 Australian megafiresDon A Driscoll, Kristina J Macdonald, Rebecca K Gibson, et al.
Pageof 27

Showing results (261-270 of 267) with videos related to

Sort By:
Pageof 27
You have reached the last page of results.This site can display upto 267 results.
Nature|July 17, 2019
Author Correction: Resonantly hybridized excitons in moiré superlattices in van der Waals heterostructuresEvgeny M Alexeev, David A Ruiz-Tijerina, Mark Danovich, et al.
The Lancet. Microbe|February 15, 2025
Safety and immunogenicity of an adjuvanted chikungunya virus virus-like particle (CHIKV VLP) vaccine in previous recipients of other alphavirus vaccines versus alphavirus vaccine-naive controls: an open-label, parallel-group, age-matched, sex-matched, phase 2 randomised controlled studyMelinda J Hamer, James M McCarty, Benjamin C Pierson, et al.
The Lancet. Infectious Diseases|August 17, 2024
Safety and immunogenicity of a next-generation live-attenuated yellow fever vaccine produced in a Vero cell line in the USA: a phase 1 randomised, observer-blind, active-controlled, dose-ranging clinical trialKayvon Modjarrad, Paul T Scott, Melanie McCauley, et al.
The Lancet. Infectious Diseases|June 30, 2023
Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trialMichael A Koren, Leyi Lin, Kenneth H Eckels, et al.
Lancet (London, England)|January 28, 2023
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trialMelinda J Hamer, Katherine V Houser, Amelia R Hofstetter, et al.
Nature Communications|August 7, 2023
Urbanisation generates multiple trait syndromes for terrestrial animal taxa worldwideAmy K Hahs, Bertrand Fournier, Myla F J Aronson, et al.
Nature|November 13, 2024
Biodiversity impacts of the 2019-2020 Australian megafiresDon A Driscoll, Kristina J Macdonald, Rebecca K Gibson, et al.
Pageof 27